PURPOSE: CRISPR/Cas has recently been adapted to enable efficient editing of the mammalian genome, opening novel avenues for therapeutic intervention of inherited diseases. In seeking to disrupt Yellow Fluorescent Protein (YFP) in a Thy1-YFP transgenic mouse, we assessed the feasibility of utilising the adeno-associated virus 2 (AAV2) to deliver CRISPR/Cas for genome modification of retinal cells in vivo.
INTRODUCTION:
Many ophthalmic diseases manifest due to well-defined genetic mutations, and inherited retinal diseases now comprise the leading cause of blind registrations in working-aged individuals.
1 Although several genetic variants across many loci have been found to cause inherited retinal dystrophies, all of these conditions are as yet currently untreatable. To-date, much work has focused on viral-mediated gene-replacement therapy, where gene expression is augmented by ectopic replacement of a normal gene product. 2 However, emerging data suggests that the efficacy of such viral-mediated genereplacement therapy reduces over time. 3, 4 Additionally, genetic heterogeneity and restrictions in viral payloads limit the broad application of such an approach for many inherited retinal diseases. [5] [6] [7] The Clustered Regularly Interspersed Short Tandem Repeat (CRISPR) and CRISPR associated protein (Cas) system used by bacteria to counter viral intrusion, has recently been adapted to allow efficient editing of the mammalian nuclear genome. 8, 9 CRISPR/Cas-based technology is particularly attractive for treating inherited diseases caused by genes with very specific spatial and stoichiometric expression. 2 There have been a small number of studies, which have demonstrated the potential of in vivo gene editing for therapeutic applications. 10 Although the first reported in vivo application of CRISPR/Cas used the endogenous homology directed repair pathway to correct the precise disease causing mutation, 11 the majority of subsequent reports have used CRISPR/Cas for gene knockout. [12] [13] [14] In postmitotic cells, such as those found in the adult retina, double stranded DNA breaks are preferentially repaired through non-homologous end joining, and as such, diseases caused by gain-of-function, dominant negative or increased copy number variants could be readily amenable to preemptive intervention whereby CRISPR/Cas technology is used to disrupt the mutant allele.
CRISPR/Cas gene editing has been applied to the retina in vivo using electroporation. 15 The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039156 doi: bioRxiv preprint first posted online Feb. 9, 2016; this intervention was found to prevent retinal degeneration and improve visual function. 16 Nonetheless, despite these promising applications it is clear that such approaches for CRISPR/Cas delivery in vivo are not currently feasible as a human therapy.
The aim of our work was to assess the feasibility and efficiency of CRISPR/Cas-mediated gene editing in the retina using a viral delivery system that could be readily adapted for use in a clinical setting. In order to rapidly quantify a phenotypic outcome for in vivo gene editing, we designed sgRNA constructs to disrupt a yellow fluorescent protein (YFP) in a transgenic mouse. As such, we report the use of a rapid, quantifiable means to explore the efficacy of a CRISPR/Cas system for retinal modification and demonstrate clear proof-of-concept evidence for gene modification in vivo.
METHODS:

Ethics Approval and Colony Maintenance:
Ethics approval for this work was obtained from the Animal Ethics Committee of the University of sgRNAs were initially cloned into the pSpCas9(BB)purov2.0 vector (a gift from Feng Zhang; Addgene plasmid #62988), 18 and the best performing sgRNAs were subsequently cloned into pX552-mCherry (a gift from Feng Zhang; Addgene plasmids #60957 and #60958). 19 pX552-mCherry was generated by replacing the GFP with mCherry using SalI and BspEI restriction sites.
Cell culture and transfection:
Stable cell lines of HEK293A and mouse 3T3-L1 expressing YFP were generated using pAS2.EYFP.puro lentivirus (RNAiCore, Academia Sinica, Taipei, Taiwan) and selected using 
Indel analysis:
Genomic DNA was extracted using QIAamp DNA mini kit (Qiagen, Chadstone, Victoria, Australia).
Indel analysis was performed with the SURVEYOR assay kit (Integrated DNA Technologies, Inc.
Coralville, USA) using 200-400ng of PCR products generated from genomic DNA of transfected cells.
SURVEYOR primers flanking the cleavage sites are listed in Supplementary Table 1 . PCR cleaved products were resolved on 1.8% TBE agarose gel and visualised using GelRed nucleic acid gel stain (Biotium, Hayward, CA, USA). The DNA band intensity was quantitated using ImageJ v1.49. 20 The percentage of indels for each sample was calculated using the method described by Ran et al. 100 x (1-
, where a is the band intensity of the undigested PCR product, and b and c are the combined intensity for the cleavage products.
21
Virus production:
Recombinant AAV2 vectors were produced in HEK293 cells packaging either pX551, containing SpCas9 or pX552-mCherry with the respective sgRNAs, and pseudo-serotyped with the AAV2 capsid (pXX2; courtesy of Ian Alexander, Children's Medical Research Institute, Westmead, NSW, Australia) as previously outlined. 22 Viral vectors were purified by AAV2pro® Purification Kit (Clontech Laboratories, Inc., Mountain View, CA, USA) and vector genomes were titred by real-time quantitative polymerase chain reaction using the following primer sets: (pX551-F:
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039156 doi: bioRxiv preprint first posted online Feb. 9, 2016; CCGAAGAGGTCGTGAAGAAG, pX551-R: GCCTTATCCAGTTCGCTCAG, pX552-F: TGTGGAAAGGACGAAACACC, pX552-R: TGGTCCTAAAACCCACTTGC) with the SYBR Green Master Mix (Life Technologies).
Intraocular Injection of AAV vectors:
A total of 22 adult mice, aged between 14 and 16 weeks, were randomly allocated to receive YFPsgRNA or LacZ-sgRNA (n=11 per group). Mice were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and xylazine (10 mg/kg). Intravitreal injections were performed using a surgical microscope similar to that previously described. 23 In brief, after making a guide track through the conjunctiva and sclera at the superior temporal hemisphere using a 30-gauge needle, a hand-pulled glass micropipette was inserted into the mid-vitreal cavity. A total of 1 µL of dual-viral suspension (AAV2-SpCas9 3x10 9 vg/µL with AAV2-LacZ-sgRNA 2.5x10 9 vg/µL or AAV2-YFP-sgRNA 3x10 9 vg/µL) or Balanced Salt Solution was injected into each eye at a rate of 100 nL/s using a UMP3-2 Ultra
Micro Pump (World Precision Instruments, Inc. Sarasota, USA). Patency was confirmed following needle removal.
Electrophysiology Assessment and Retinal morphology:
Mice were euthanized five weeks after intraocular injection. Immediately prior to terminal anesthesia, electroretinography was used to assess retinal function in six mice treated with SpCas9/YFP-sgRNA and six mice treated with SpCas9/LacZ-sgRNA.
Our methods for electroretinogram recordings have been well described previously. [24] [25] [26] In brief, overnight dark-adaptation (minimum 12 hours) was performed and all animals were prepared for recording under dim red illumination. Following general anesthesia (intramuscular ketamine 80 mg/kg, xylazine 10 mg/kg), pupil dilation and corneal anesthesia were obtained with 0.5% tropicamide and 0.5% proxymetacaine, respectively. A Ganzfeld sphere (Photometric Solutions International, Oakleigh, Victoria, Australia) was used to delivery luminous energy ranging from −6.26 to 2.07 log cd·m 
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Retinal morphology was assessed in vivo using spectral domain optical coherence tomography (OCT)(Micron III; Phoenix Research Labs, Pleasanton, CA, USA). As described previously, immediately following ERG recordings, a total of ten horizontal scans across the retina centered at the optic nerve head were obtained and averaged. 27 Total retinal thickness, retinal nerve fibre layer and ganglion cell layer thickness were measured.
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Retinal Tissue processing:
Enucleated eyes were fixed in 4% paraformaldehyde (PFA; ProSciTech, Australia) for 1 hour, and retinal flat mounts were prepared and stained with a 4',6-diamidino-2-phenylindole (DAPI; 0.2 ug/mL, Sigma-Aldrich, Sydney, NSW, Australia) counterstain. For histological assessment, enucleated eyes were fixed in 4% PFA for 1 hour and embedded in optimal cutting temperature compound prior to frozen sectioning on a microtome-cryostat. Serial 10 µm thick sections were cut, mounted on silanated glass slides, and then stained with DAPI.
Retinal imaging, cell counting and statistical analysis:
A fluorescence microscope (Zeiss Axio Imager Microscope, Carl-Zeiss-Strasse, Oberkochen,
Germany) equipped with a charge-coupled device digital camera (Axiocam MRm, Zeiss) and image acquisition software (ZEN2, Zeiss) was used. Following whole mounting, each retinal quadrant was photographed using an appropriate filter for the fluorescence emission spectra of mCherry (605nm, Zeiss Filter set 64HE) and YFP (495nm, Zeiss Filter set 38HE). Confocal images were taken using a Nikon C1 confocal laser scanning microscope using a 20x 0.75NA lens and images were tile stitched using the NIS Elements AR program (Nikon, Melville, NY, USA). Retinal cell quantification was performed using individual fluorescent images captured at 400x magnification. A total of 18 images from four eyes treated with SpCas9/LacZ-sgRNA, and 26 images from five eyes treated with SpCas9/YFP-sgRNA were quantified manually using using ImageJ v1.49, by an experienced grader (AFL), masked to treatment status. 20 Sample group decoding was performed only once data were quantified and analyzed. 
RESULTS:
sgRNA Selection and in vitro Validation:
We assessed three sgRNAs targeting the YFP sequence, together with a LacZ-sgRNA control, 19 for cleavage efficiency in 3T3-L1-YFP cells ( Figure 1A ). Indel analysis, for the quantification of sgRNAinduced nucleotide mismatches revealed that one of our sgRNAs (designated "YFP KO sgRNA2")
targeted YFP most effectively ( Figure 1B) . With approximately 13% cleavage activity this YFPsgRNA was used for all subsequent experiments ( Figure 1B) . When transfected into HEK293A-YFP cells, our selected YFP-sgRNA resulted in almost complete reduction in yellow fluorescence compared with untransfected and LacZ sgRNA controls ( Figure 1C ).
In vivo AAV delivery and gene targeting of CRISPR/Cas9 in the mouse retina:
To evaluate the YFP disruption in vivo by CRISPR/Cas-mediated gene-editing, Thy1-YFP mice There was no statistically significant difference in retinal morphological profiles in situ, between treated or contralateral controls eyes (Supplementary Figure 4) . In particular the retinal nerve fibre layer thickness and ganglion cell complex thickness as measured by OCT did not significantly differ between eyes treated with YFP-sgRNA and contralateral control eyes (RNFL p=0.30, GCC p=0.80) or between LacZ-sgRNA and their control eyes (RNFL p=0.70, GCC p=0.39).
DISCUSSION:
We have successfully demonstrated viral-mediated delivery of essential CRISPR/Cas components to 9, 2016; (95% CI: 81. 8-86.9 ). This level of gene modulation in vivo is similar to that reported for other tissues, such as brain (~68% using AAV) and liver (80-90% using adenovirus). 19, 28 Our study builds on recent work, where CRISPR/Cas system was introduced into rodent retinas using an electroporation delivery method. 15, 16 By demonstrating that CRISPR/Cas can also cause substantial gene modification activity when introduced by a viral delivery method in the retina, we are closer to translating gene-editing technology for therapeutic purposes. Importantly we found that AAV2-delivered SpCas9 was not retinotoxic over a five week treatment period. Nonetheless, it is clearly possible that adverse effects from ongoing or prolonged CRISPR/Cas expression could arise. As such it will be important to continue to develop CRISPR/Cas systems that could be tightly regulated and thereby be able to create an optimal window for gene modification while reducing the chance for potential off-target activity. warranted.
An important limitation of our work, is the fact that off-target effects were not directly quantified.
Nonetheless, to some extent this is a minor consideration for our initial proof-of-concept work which sought to primarily assess "on-target" efficacy of virally delivered CRISPR/Cas in the adult retina.
. CC-BY 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/039156 doi: bioRxiv preprint first posted online Feb. 9, 2016; Additionally, it is well appreciated that CRISPR/Cas technology is advancing rapidly and although a major limitation of gene editing has been the prospect of off-target effects, this issue is being addressed. 37, 38 For example, with careful design of the guide RNA (using a double-nick; truncated sgRNA) it is already possible to avoid most off-target cuts and recently, two independent studies report modifications to SpCas9, which can dramatically reduced off-target activity. 37, 38 Regardless, it is clear that safety will be paramount prior to CRISPR/Cas being used in mainstream medical care, and offtarget profiling will need to be considered before current research is translated into clinical trials.
In summary, this work suggests that a relatively high-efficiency of gene editing in the retina can be achieved by a dual AAV2-mediated CRISPR/Cas system. Whilst ex vivo TALEN-based approaches are now in clinical trials, given the versatility and relative ease of design, CRISPR/Cas techniques appear to be more clinically applicable. Inherited eye diseases share several features that make them appealing for the application of in vivo gene editing. For example, non-syndromic retinal diseases generally have a specific and well-defined pathogenesis, whereby only a specific subpopulation of cells would need to be targeted. Additionally, following any intervention, the eye can be directly examined for the development of any adverse effects and enucleated if necessary. Nonetheless, any in vivo gene editing therapies will require a number of functionally active cells, and it is possible that the threshold for viable cells will vary across genes and diseases.
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